Clinical studies on infectious diseases usually are dealing with patients who have been diagnosed because of their symptomatic clinical presentation. First data about the course of neopterin concentrations during the development of infections became available when allograft recipients, of whom neopterin concentrations were m onitored on a daily basis to detect immunological complications early, acquired viral infections during their stay at the hospital post transplantation. In a patient who received a liver allograft and developed cytomegalovirus infection, a dramatic increase of neopterin concentrations occurred already 3 weeks before CMV IgG seroconversion, after that neopterin concentrations declined and finally normalised (5) . Similar observations were made with two children who developed rubella. In both cases an increase of neopterin concentrations was observed days before exanthema became visible and IgM seroconversion occurred (6) . These observations fully agreed with earlier data available from vaccination protocols, e.g . exposure to measles life vaccine was associated with highly increased neopterin concentratIOns several days befort' seroconversion, even w hen volunteers relT'.ained fully asymptomatic (7) . Finally in patients w ith acute HIV -1 infection the same deve lopment of neopterin concentrations was seen (8-1 0) . N eopterin concentrations increased rapidly after mfection and were above the 98 th percentile of healthy persons (> 10 nM) when HIV -specific p24 antigen became detectable (8) . After seroconversion neopterin concentrations declined, howe ver, in most cases remaining above the upper limit of normal (Fig. 1 ,  refs . 1,8,9 ) . This kinetic of neopterin concentrations could also be confirmed in animal model systems for HIV infection, namely rhesus macaques exposed to SIV (11, 12) . More recently comparable observations were made in patients with acute hepatitis A and B virus infection (10) and in an animal model with yellow fever virus (13) . In sum, infections with any type of virus, DNA-, RNA-and lymphotropic retrovirus, seemed to evoke an almost identical pattern of neopterin concentrations: an increase during the acute phase of infection, followed by seroconversion and concomitant reduction and normalisation of neopterin levds ( Fig.I) with the exception of HIV and SIV, in which neopterin concu;,' !trations remained higher than baseline also in the asymp-tomatic pn.:s'O: of infection. In 1981, the acquired immunodeficiency syndrome was first described, and its viral origin was p inned down in tum. Sexual intercourse was elucidated as the central background of HIV transmIssion, but soon after transmission of HTV via blood or blood components was recognised. In 1985 anti-HI V antibody screening of blood donations was introduced in the Western world, reducing the risk of unrecognized HIV -containing blood donations to the gap of a few weeks between infection and seroconversion.
Definitely the introduction of HIV antibody screening tests into blood donation services has almost completely eradicated the risk of HIV transmission by blood or blood components lowering the risk to approximately 1 per 1,000.000 donors in most European countries. However, the history of AIDS has told us that newly developing viruses will always represent a risk for blood transfusion, as long as only specific tests are applied for screening. In the case of AIDS the infectious agent was isolated rather quickly after the syndrome was identified as potentially infectious. It has taken around a decade from the begin of the spread of HIV in the U.S. till the disease was recognised and another 5 years until the virus was isolated and antibody screening tests became available. In Austria 41 AIDS cases were diagnosed due to HIV transmission by blood transfusion and another 77 hemophilia patients developed AIDS due to HIV infection mostly because of the "natural" delay between the starting point of HIV spread, characterisation of the new agent and introduction of screening tests.
Because of its nature as a marker of immune response, neopterin concentrations increase during various virus infections early and thus additional neopterin screening was thought to possibly serve as a kind of umbrella against several agents including even those which are not yet recognised or newly developing viruses or mutants with high probability. In 1986, additional neopterin screening was introduced in blood transfusion services in the Austrian Tyrol. In a first study the cut off for neopterin concentrations was set to 10 nM, which corresponded to the 98 th percentile, thus tolerating a donor loss of 2%. Within this 2 percent of anamnestically normal donors, several transient or chronic diseases were diagnosed during follow up which were listed among diseases to be excluded within the transfusion guidelines (14) . Since 1994, additional screening of blood donations by an indicator of immune activation became mandatory in whole Austria. In the following years, a number of studies has been conducted to further proof the capability of neopterin screening to improve safety of blood donations regarding the transmission of virus infections.
Incidence of virus infections in donations with elevated versus normal neopterin concentrations
Cytomegalovirus (CMV) infection and neopterin in blood donations : In the first evaluation of neopterin screening, it was found that 3.7 % of donations with elevated neopterin concentrations were from otherwise inconspicious donors with CMV 19M seropositivity (14) . To further inves-tigate the possible as<;ociation between increased neopterin concentrati rms and acute CMV infection in blood donors, of almost 100.000 blood donations CMV IgM ELISA was performed in those with elevated neopterin concentrations (n=1767) and compared with randomly selected donors with low neopterin concentrations (n=1092). It tul'led out that the frequency of CMV IgM seropositive (!onors was 19.2-fold higher in the group with elevated Tleopterin concentrations (ref. 15 ; Table 1 ). This result :::hows that the additional neopterin screening has reduced the risk of acute CMV infection to almost 0.05 2 . Besides, it turned out that some of the donors witt: elevated neopterin concentrations but an initially nega tive CMV IgM test result developed CMV IgM antibOdies 2 -4 weeks thereafter (Fig.2) , thus indicating t:':at neopterin screening was able to detect developing acute CMV infection before seroconversion in these donors.
Epstein Barr Virus (EBV) infection and neopterin in blood donations: Young adults may present with a rather high frequency of acute EBV infection. Acute EBV infection was found to be associated with sometimes extremely high neopterin concentrations (16, 17) . A representative course of urinary neopterin concentrations in a patient with acute EBV infection is Human parvovirus B 19 (PY B 19) infection and neopterin in blood donations: PV B 19 infection is very resistant to plasma inactivation and therefore represents a special risk for blood transfusion services . Of 1060 inconspicious donors with increased neopterin concentrations, 73 were seropositive for PV B19 IgM (6.9 %) compared to lO out of 462 controls (2.2 % ) with normal neopterin concentrations (18) .
From the data one can estimate that additional neopterin screening reduced the risk of acute PV B 19 infection by a factor of 3.34 (p < 0.001; Table 1 ).
These data were extended to investigations applying polymerase chain reaction (pcr), and it turned out that all donations testing positive for PV B 19 by virus specific pcr (= infectious) presented with increased neopterin concentrations, whereas none of the donations with low neopterin concentrations had detectable PV B19 by pcr (19) .
Hepatitis C virus (HCV) infection and neopterin in blood donations: Since 1990, when specific antibody testing for HCV infection became available, additional screening of blood donations is performed in Austria. In 328 HCY antibody seropositive donations (0.60%) the reactivity of HCV pCI' was compared in donations with and without elevated neopterin concentrations (20) . Seropositivity by pcr was significantly more frequent in donations with elevated neopterin concentrations compared to normaL Overall, the study shows that additional neopterin screening of blood : ::
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Summary and discussion
In several studies the theoretical background could be confirmed that additional neopterin screening of blood donations can serve as an umbrella against various infectious viruses. This was shown for CMV, EBV, parvovirus B 19 and also for HCV, and from further clinical studies it can be deduced that this is true also for other agents not specifically screened for . In addition, there are numerous clinical conditions like malignancy or chronic inflammatory disorders, which are listed within the guidelines of blood transfusion to be excluded from donations and which are associated with increased neopterin concentrations (2) . Thus, the available data are in line with the protective effect of neopterin screening especially for infectious agents which are not frequent enough to justify specific screening. The observations made when patients with acute infections were monitored by neopterin screening further imply that additional neopterin screening also reduces the window-period between exposure to an agent and seroconversion, since the raise of neopterin screening starts very early in acute infections preceeding symptoms and seroconversion (Fig.! ) . Additional neopterin screening of blood dou ations may also represent a barrier against newly d t:.veloping agents. In these days new discussion is emerging with regard to a potential risk of spongiform encephalitis to be possibly transmitted via bloo d and blood components (21) . This aspect reminds to the discussion when HIV was fo und to potentially hazardous to recipients of blood donations and hemophilia patients. AlthC'llgh it is premature to speculate whether new variant Creutzfeld Jacob disease represents a rel c:vant risk for blood donations services, the ongoing discussion shows that there wi1l be always the risk f.)r newly developing agents being potentially hazard ous also for blood transfusion services. Within this context it has to be mentioned, that in one paijent with classical Creutzfeld Jacob disease elevat : d neopterin concentration has been described in ' ..he blood at diagnosis (22) . This single case does nrJt allow much of a conclusion for blood transfusion settings, however it indicates that increased Jleopterin concentrations might have existed in this pattent at least some period before diagnosis of Creutzfeli Jacob disease was established. In conclu sion, frequencies of acute virus infections as detected by virus-specific IgM tests are significantly increased in donations with elevated neopterin concentrLtions. Thus, additional screening of blood donatiom; for elevated neopterin concentrations significan tly improves safety of blood transfusions regarding various viral pathogens in a non-specific way, although no 100% safety can be achieved.
